2Sonenberg GE,Garg DC,Weidler DJ,et al.Short term comparison of on ce versus twice daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.Ann harmacother,1997,31:671.
3Riddle MC.Glyvemic management of type 2 diabetes:an emerging strategy with oral agents,insulins,and combinations.Endocrinol Metab Clin North Am,2005,34:77-79.
二级参考文献2
1K Bando,Y Yamada.Glimepiride (Amaryl):a review of its pharmacological and clinical profile.Nippon Yakurigaku Zasshi,2001,118:59-67.
2Riddle MC.Glycemic management of type 2 diabetes:an emerging strategy with oral agents,insulins,and combinations.Endocrinol Metab Clin North Am,2005,34:77-98.
7Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group [ J ]. Horm Metab Res, 1996,28 ( 9 ) :426-429.
8Draeger KE, Wernicke-Panten K, Lomp H J, et al. Long- term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide[ J]. Horm Metab Res, 1996, 28(9) :419-425.
9Inukai K, Watanabe M, Nakashima Y, et al. Efficacy of glimepiride in Japanese type 2 diabetic subjects[ J]. Diabe- tes Res Clin Pract, 2005,68 ( 3 ) :250-257.
10Koshiba K, Nomura M, Nakaya Y, et al. Efficacy of glimepiride on insulin resistance, adipocytokines, and ather-osclerosis [ J ]. Journal of Medical Investigation, 2006,53 ( 1 - 2) : 87-94.
